LEADER 00812nam0-2200241 --450 
001 9910837087903321
005 20240313171127.0
100   $a20240313d1962----kmuy0itay5050    ba
101 0 $aita
102   $aIT
105   $a        001yy
200 1 $aUdito e linguaggio dal punto di vista neurobiologico$eAttivitą neuromuscolari e conseguenze propriocettive$fV. M. Buscaino
210   $aNapoli$c[s. n.]$d1962
215   $a637-652 p.$d25 cm
300   $aEstratto da: Acta neurologica. v. XV, n. 6 Novem.-dicem. 1962
700  1$aBuscaino,$bVito Maria$0160667
801  0$aIT$bUNINA$gREICAT$2UNIMARC
901   $aLG
912   $a9910837087903321
952   $aDAM OPUSC. 18 (22)$b2024/1863$fFLFBC
959   $aFLFBC
996   $aUdito e linguaggio dal punto di vista neurobiologico$94132446
997   $aUNINA

LEADER 03085nam  22006975  450 
001 9910300343403321
005 20200704011624.0
010   $a3-319-03059-0
024 7 $a10.1007/978-3-319-03059-3
035   $a(CKB)3710000000248987
035   $a(EBL)1965147
035   $a(OCoLC)908083279
035   $a(SSID)ssj0001354146
035   $a(PQKBManifestationID)11758992
035   $a(PQKBTitleCode)TC0001354146
035   $a(PQKBWorkID)11335498
035   $a(PQKB)11496774
035   $a(MiAaPQ)EBC1965147
035   $a(DE-He213)978-3-319-03059-3
035   $a(PPN)181346443
035   $a(EXLCZ)993710000000248987
100   $a20140925d2014      u|         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aGuide to Targeted Therapies: EGFR mutations in NSCLC /$fby Federico Cappuzzo
205   $a1st ed. 2014.
210  1$aCham :$cSpringer International Publishing :$cImprint: Adis,$d2014.
215   $a1 online resource (75 p.)
300   $aDescription based upon print version of record.
311   $a3-319-03058-2 
320   $aIncludes bibliographical references at the end of each chapters.
327   $aIntroduction -- The Human Epidermal growth factor Receptor (HER)?family:?structure and function -- Methods for EGFR mutation testing -- Predictive and prognostic implications of EGFR mutations -- EGFR-targeted therapies in non?small cell lung cancer -- Conclusions.
330   $aGuide to Targeted Therapies: EGFR Mutations in NSCLC is a speedy and up-to-date review, which discusses EGFR mutations, testing methods and technology, current and emerging therapies, and resources that clinicians can provide to their patients. Busy healthcare professionals who want a quick review of EGFR gene mutations as well as a summary of current therapies will benefit from this succinct guide.
606   $aMedicine
606   $aOncology
606   $aChemotherapy
606   $aRespiratory organs?Diseases
606   $aMedicine/Public Health, general$3https://scigraph.springernature.com/ontologies/product-market-codes/H00007
606   $aOncology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33160
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
606   $aPneumology/Respiratory System$3https://scigraph.springernature.com/ontologies/product-market-codes/H33134
615  0$aMedicine.
615  0$aOncology.
615  0$aChemotherapy.
615  0$aRespiratory organs?Diseases.
615 14$aMedicine/Public Health, general.
615 24$aOncology.
615 24$aPharmacotherapy.
615 24$aPneumology/Respiratory System.
676   $a610
676   $a615.1
676   $a616.2
676   $a616994
700   $aCappuzzo$b Federico$4aut$4http://id.loc.gov/vocabulary/relators/aut$0755671
906   $aBOOK
912   $a9910300343403321
996   $aGuide to Targeted Therapies: EGFR mutations in NSCLC$91522809
997   $aUNINA